← Back to Search

Diagnostic Tests for Pediatric Septic Arthritis

N/A
Recruiting
Led By Emily R Dodwell, MD, MPH
Research Sponsored by Hospital for Special Surgery, New York
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Synovial fluid is obtained to assess for infection or inflammatory/rheumatologic disease (all medium and large joints will be included: hip, knee, ankle, shoulder, subtalar, elbow, and wrist joints)
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up interim analysis at 2 years of study recruitment
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing different ways to figure out if a child has septic arthritis, which is a serious infection of the joints.

Who is the study for?
This trial is for children with joint inflammation who are undergoing procedures to assess for infection or inflammatory diseases. It includes those with recent antibiotic use, covering various joints like the hip, knee, and shoulder. Children not being assessed for infection-related procedures are excluded.
What is being tested?
The study tests several synovial biomarkers' ability to diagnose pediatric septic arthritis quickly and accurately. This includes assays for alpha-defensin, neutrophil elastase, bacterial cultures, antigen panels, lactate levels among others compared to standard blood tests.
What are the potential side effects?
Since this trial involves diagnostic testing rather than treatment interventions, there are no direct side effects from the tests themselves; however routine risks associated with drawing blood and obtaining synovial fluid may apply.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had fluid taken from my joints to check for infection or inflammation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~interim analysis at 2 years of study recruitment
This trial's timeline: 3 weeks for screening, Varies for treatment, and interim analysis at 2 years of study recruitment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sensitivity and specificity of experimental tests

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Inflamed/Infected JointExperimental Treatment19 Interventions
Patients undergoing joint aspiration/debridement due to suspicion of septic joint or rheumatologic/inflammatory condition
Group II: Normative ControlActive Control19 Interventions
Patient undergoing procedure unrelated to infection/inflammation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Serum Procalcitonin
2014
N/A
~110

Find a Location

Who is running the clinical trial?

Hospital for Special Surgery, New YorkLead Sponsor
250 Previous Clinical Trials
60,894 Total Patients Enrolled
Campbell ClinicOTHER
13 Previous Clinical Trials
1,566 Total Patients Enrolled
Pediatric Orthopaedic Society of North AmericaOTHER
7 Previous Clinical Trials
1,018 Total Patients Enrolled

Media Library

Synovial PCR for Kingella kingae Clinical Trial Eligibility Overview. Trial Name: NCT03704766 — N/A
Joint Infections Research Study Groups: Normative Control, Inflamed/Infected Joint
Joint Infections Clinical Trial 2023: Synovial PCR for Kingella kingae Highlights & Side Effects. Trial Name: NCT03704766 — N/A
Synovial PCR for Kingella kingae 2023 Treatment Timeline for Medical Study. Trial Name: NCT03704766 — N/A
~21 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top